Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on SABIEN TECHNOLOGY GROUP PLC. We currently have 4 research reports from 2 professional analysts.
|30Dec16 10:05||RNS||Holding(s) in Company|
|29Nov16 12:19||RNS||Result of AGM|
|29Nov16 10:41||RNS||AGM Statement|
|07Nov16 05:28||RNS||Notice of AGM|
|25Oct16 07:00||RNS||Final Results|
|29Sep16 03:25||RNS||Holding(s) in Company|
|22Sep16 04:56||RNS||Holding(s) in Company|
Frequency of research reports
Research reports on
SABIEN TECHNOLOGY GROUP PLC
SABIEN TECHNOLOGY GROUP PLC
Pilot programme working
03 May 16
We are most encouraged by today’s update on the pilot programme in which the company has said it is on track to complete at least 34 pilots in the 2015-16 heating season. This compares to eight in 2014-15 and its target of up to 35 this financial year. Importantly, there is already the positive anticipated traction on the sales pipeline with 10 of those completed, adding an expected £3.5m. With a trading update scheduled for early June, we make no changes to any of our forecasts and reiterate our 50p DCF-derived TP and Buy rating.
Pilot programme showing promise
09 Feb 16
The key elements of the interims in our view are that 30 UK pilots have been agreed for this heating season and that the sales pipeline has increased to £6.4m from the last-reported £5.8m. As anticipated the adj. LBT increased to £1.0m in the first half due to the extra costs incurred in increasing the pilot programme. It is encouraging that the company still anticipates meeting expectations for FY2016. With no changes in our forecast of the move towards profitability in FY2017, we reiterate our 50p DCF-derived TP and Buy.
Breaking through the glass ceiling
20 Jul 15
Sabien’s profitability has depended on whether a substantial contract shipped or not. In order to boost the size of its sales pipeline and potentially the speed of conversion, Sabien has raised c.£0.7m net to introduce a more aggressive piloting strategy. It will offer a “free” pilot instead of charging c.£20k and increase the number of pilots it runs in a year from 10 in FY2015, to up to 35 in FY2016 and 50 in due course. There will be extra costs in the shorter-term, but our 50p DCF-derived TP and Buy rating remain intact.
The Slide Rule
12 Jan 17
What is The Slide Rule? The Slide Rule has been designed to dramatically simplify the identification of the best companies in the UK small/mid-cap sector by making a quantitative assessment of the relative potential of each company. At its core, The Slide Rule aims to identify those companies that create genuine shareholder value through strong returns on capital and solid growth, but also present a value opportunity with the potential tailwind of earnings momentum. Companies are assessed within a Quality, Value, Growth and Momentum (QVGM) framework.
16 Jan 17
We take a look at the rankings of the various countries in Africa that have a significant exposure to mining. We take the Transparency International corruption rankings as our starting point and modify these for exceptional geology and for current UK government travel warnings. Ghana, Botswana and Namibia come out as our top three, with Eritrea, Kenya and Zimbabwe at the bottom of our rankings.
Small Cap Breakfast
17 Jan 17
Global Energy Development (GED.L) — To be renamed Nautilus Marine Services. Schedule 1 from developer and seller of hydrocarbons and related products. Reverse takeover. Raising $10.5m via a convertible. Expected 9 Feb. Eco (Atlantic) Oil & Gas—TSX-V listed oil and gas exploration has announced its intention to float on AIM. Assets in Guyana and Namibia. Proposed £2m-£3m fundraise. Diversified Gas & Oil—According to LSE website first day of trading on AIM now expected for 30 January.
N+1 Singer - St Ives - Downgrade
19 Jan 17
Marketing activation has been impacted by further decline in grocery retail impacting profit by c£5m. Strategic The Company is also taking this opportunity to revise its guidance for Strategic Marketing as its recovery pace is not running at the planned target rate. PBT falls from N1Se £31.9m to £25m. The Company expects dividend to be held based upon lowered guidance and the implied cash flow performance. There do not appear to be any covenant issues. Forecasts and TP under review and downgrade to Hold. We expect the shares to test the 100p level.
N+1 Singer - Northern lights - Shining prospects for 2017
16 Jan 17
As the birthplace of Stephenson, Armstrong and Swan, the North East of England has a proud history of industrial and technological innovation. Despite local economic challenges, the region’s industrial heritage lives on through continuing success in high end engineering and technology. The recent takeovers of private equity backed SMD (subsea robotics) and Nomad Digital (wi-fi on the railways) are testament to this. The North East has also emerged as a leader in genetics and genomics with an enviable life sciences and healthcare infrastructure. Against this backdrop, we expect the region to continue to throw up attractive IPO candidates to build on the six new listings in the past three years. We expect 2017 to be far kinder to the existing portfolio of North East plcs than 2016 (a year to forget) with recent management changes one important theme for the new year. Our top picks are Hargreaves Services, Quantum Pharma and Zytronic (all N+1 Singer Corporate clients) and we are Buyers of Northgate and Grainger.
N+1 Singer - Morning Song 19-01-2017
19 Jan 17
Actual Experience (ACT LN) 2017 – a milestone year for revenue | Bagir Group (BAGR LN) Independent NED appointment to strengthen Board composition | Bioquell (BQE LN) Reassuring pre-close statement | Carador Income Fund (CIFU LN) Q4 dividend increased to 2.75c, 0.5c higher than forecast | FreeAgent (FREE LN) Contract with Royal Bank of Scotland | Halfords Group (HFD LN) Excellent Q3 update, special divi and confidence in FX mitigations | N Brown Group (BWNG LN) Robust peak trading with reversal of drag from older titles | NCC Group (NCC LN) Interims confirm underlying business sound | St Ives (SIV LN) Downgrade | Summit Therapeutics (SUMM LN) Dr David Roblin appointed Chief Operating Officer and R&D President | Wilmington Group (WIL LN) Acquisition – Further scaling of Healthcare